Anti-depressant, Proton Pump Inhibitor Lead First-Half 2003 Promotion to Key Managed Care Executives, Cognet-X Inc. Reports.Business Editors/Health/Medical Writers FEASTERVILLE, Pa.--(BUSINESS WIRE)--Sept. 9, 2003 Forest Laboratories Inc.'s Lexapro and TAP Pharmaceuticals TAP Pharmaceuticals is an Japanese pharmaceutical company. It is a joint venture between Abbott Laboratories and the Japanese Takeda Pharmaceutical Company, formed in 1977. Inc.'s Prevacid were the prescription drugs most heavily promoted to managed care pharmacy directors during the first 6 months of 2003, Cognet-X Inc. data show. Lexapro, the newer of Forest Laboratories two anti-depressants, also emerged as the most promoted brand during the second quarter, according to according to prep. 1. As stated or indicated by; on the authority of: according to historians. 2. In keeping with: according to instructions. 3. Cognet-X's PAR-Rx (Promotional Assessment Research) Report(TM). The PAR-Rx Report tracks pharmaceutical company promotion to pharmacy directors at the most influential managed care organizations and pharmacy benefit management A Pharmacy Benefit Manager (PBM) is a third party administrator of prescription drug programs. They are primarily responsible for processing and paying prescription drug claims. companies in the country. In addition, second-quarter PAR-Rx data show that TAP's Prevacid generated more contacts to PAR-Rx panelists than did any product other than Lexapro. Prevacid also held the second-place spot during the first quarter of the year. Strattera, Eli Lilly & Co.'s Attention Deficit/Hyperactivity Disorder Attention deficit/hyperactivity disorder A persistent pattern of inattention, hyperactivity and/or impulsiveness; the pattern is more frequent and severe than is typically observed in people at a similar level of development. (ADHD Attention-Deficit/Hyperactivity Disorder (ADHD) Definition Attention-deficit/hyperactivity disorder (ADHD) is a developmental disorder characterized by distractibility, hyperactivity, impulsive behaviors, and the inability to remain focused on tasks or ) product, which launched in the first quarter, placed third in terms of total first-half promotion. Strattera generated only one contact less than Prevacid and three less than Lexapro. In fourth place during the first half of 2003 was Aventis Pharmaceuticals' non-sedating antihistamine antihistamine (ăn'tĭhĭs`təmēn), any one of a group of compounds having various chemical structures and characterized by the ability to antagonize the effects of histamine. , Allegra Al·leg·ra A trademark for the drug fexofenadine hydrochloride. fexofenadine hydrochloride Allegra, Telfast (UK) Pharmacologic class: Peripherally selective piperidine, selective histamine , followed by Lilly's new osteoporosis injectable, Forteo, in fifth position. Allegra promotion spiked upward in the second quarter, generating more contacts to PAR-Rx panelists than any products besides Lexapro and Prevacid. Allegra's rival, Schering-Plough Corp.'s Clarinex, was one of two products to finish the second quarter in fourth place; GlaxoSmithKline's new antidiabetic agent, Avandamet tied with Allegra as the fourth most promoted brand. Four products tied to be the fifth most promoted brand, according to the PAR-Report: Astelin from MedPointe Inc., Cardizem LA from BioVail Pharmaceuticals, Emend e·mend tr.v. e·mend·ed, e·mend·ing, e·mends To improve by critical editing: emend a faulty text. from Merck & Co. Inc. and Wyeth's Protonix. About the PAR-Rx Report Cognet-X's PAR-Rx Report is a year-round service that provides the pharmaceutical industry with real-time, Internet-based competitive intelligence on pharmaceutical company promotion to influential managed care pharmacy directors. The Report offers Cognet-X clients the ability to evaluate and analyze variable differences that are critically important to their decision-making process. The Report collects comprehensive data that can be segmented and analyzed to provide clients with "21st-Century solutions to their 21st-Century challenges." About Cognet-X Cognet-X offers the pharmaceutical industry market research, consulting and software development that help companies build and refine their relationships with numerous customer bases, including the managed care community. Based in Bucks County, Pennsylvania Bucks County is a county located in the U.S. state of Pennsylvania. As of 2000, the population was 597,635. A 2004 U.S. Census estimate placed the population at 621,342, making it the fourth most populous county in Pennsylvania, after Philadelphia, Allegheny, and Montgomery , Cognet-X is privately held and employee-owned. For more information on the PAR-Rx Report or other valuable Cognet-X products, please contact James A. Barone at (215) 396-8300 (extension 102) or Rick Bourland (extension 103) or via e-mail at jimb@cognetx.com or rickb@cognetx.com. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion